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Background: Several models have been developed to help the
clinician in risk stratification for Acute Coronary Syndrome (ACS),
such as the TIMI and GRACE risk scores. However, there is conflicting
evidence for the prognostic value of NT-ProBNP in acute myocardial
infarction (AMI).
Objective: (1) To explore the association of NT-proBNP with 30-day
clinical outcome in AMI patients. (2) To compare the prognostic value of
NT-proBNP with TIMI and GRACE risk scores in AMI patients.
Methods: We conducted a multicenter, prospective observational
study recruiting patients presented with AMI between 29-October-2015
and 14-January-2017, involving 1 cardiology referral centre and 4 non-
cardiology hospitals. NT-proBNP level (Alere Triage®, US)wasmeasured
within 24 hours from the diagnosis of AMI. Patientswere followed-up for
1 month.
Results: A total of 186 patients were recruited, 143 from tertiary
cardiology centre and 43 from non-cardiology hospitals. Mean age was
54.7±10.0 years, 87.6%male and 64%were STEMI. The NT-proBNP level
ranged from 60 to 16700pg/ml, with a median of 714pg/ml. Using the
75th centile as the cutoff, Kaplan-Meier survival analysis for the 30-day
cardiac related mortality was significantly higher for patient with
NT-proBNP level of ≥1600pg/ml (6.4% vs. 0.7%, p=0.02). Cox-regression
analysis showed that NT-proBNP level of ≥1600pg/ml was an indepen-
dent predictor of 30-day cardiac relatedmortality, regardless of TIMI risk
score, GRACE score, LV ejection fraction and study hospitals (HR 9.274,
p=0.054, 95%CI 0.965, 89.161). Readmission for heart failure at 30-day
was also higher for patient with NT-proBNP level of ≥1600pg/ml
(HR 9.308, p=0.053, 95%CI 0.969, 89.492). NT-proBNP level was not
associated with all-cause mortality, risk of readmission for ACS,
arrhythmia and stroke (pN0.05). By adding 50 score to GRACE risk score
for NT-proBNP level of ≥1600pg/ml, combination of GraceNT-proBNP
scores of more than 200 appeared to be a better independent predictor
for 30-day cardiac related mortality (HR:28.28, p=0.004, 95%CI 2.94,
272.1). ROC analysis showed that this new score had 75% sensitivity and
91.2% specificity in predicting 30-day cardiac related mortality (AUC
0.791, p=0.046).
Conclusions: NT-proBNP is a useful point-of-care risk stratifica-
tion biomarker in AMI. It can be combined to the current risk score
model for better risk stratification in AMI patients.
doi:10.1016/j.ijcard.2017.09.112
“CAS-FIRST” Investigational Approach for Stable Chest Pain: A
2-year Outcome Single-Centre Study
Abdul Rahman E., Najme Khir R., Othman N., Chuah S.C., Ibrahim K.S., Lim
C.W., Mohd Arshad M.K., Ibrahim Z.O., Ismail J.R., Zainal Abidin H.A.,
Kasim S.S.
Faculty of Medicine, Universiti Teknologi MARA, Sg Buloh, Malaysia
Introduction: Cardiovascular (CV) risk factors are highly preva-
lent in south east Asia and current risk scoring systems have been
proven to have some drawbacks. Calcium score (CAS) has emerged
as a potential marker to improve risk prediction however data is
lacking on its utility in a population with high CV burden.
Objective: We aim to test the diagnostic performance of CAS in
comparison to Framingham risk score (FRS) in a sample of Malaysian
population presented with stable chest pain to an outpatient setting.
Method: This was a single-centre retrospective study of patients
referred for coronary CT angiography (CTCA) for investigation of
stable chest pain in 2014. Their baseline clinical data such as
demographics, CV risk profiles, CAS and CTCA results were obtained
from electronic medical records. A combined clinical outcome of CV
event such as acute coronary syndromes and revascularization that
occurred over a period of 2 years were also traced.
Result: Out of 240 patients referred for CTCA, 130 patients with
complete data and remained under follow-upwere analzyed. Themean
age was 54±11.6 years. 66% (86 patients) were males and 32%
(49 patients) were diabetics. The disease prevalence in this cohort was
26%. Over a period of 2 years, CV event occurred in 34 patients, of which
mostly occurred in patients with CAS N400 and high FRS risk (16
patients). Out of 53 high FRS-risk patients, CAS downgraded 33 patients
to “lower” risk with the largest shift occurred when CAS was zero.
Detectable calcium upgraded 3 out of 39 low FRS-risk patients to
“higher” risk. Out of 35 patients with intermediate FRS-risk, CAS
downgraded 23 patients to “lower” risk and upgraded 11 patients to
“higher” risk.WhenCASwas added to FRS in a statisticalmodel, the area
under ROC curve improved from 0.67 to 0.92 in detection of obstructive
CAD by CTCA and 0.65 to 0.85 in detection of CV outcome.
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